During the corresponding time, Tela Bio Inc recorded a revenue increase by 0.97 % year on year, sequentially revenue grew by 4.16 %. While revenue at the Tela Bio Inc 's corporate clients
Tela Bio Inc's Comment on Sales, Marketing and Customers
The company markets its products primarily through a direct sales force based mainly in the United States, with additional sales representatives in the United Kingdom and European Union. It also utilizes independent contractors and distributors in the U.S. and certain European countries. The company holds contracts with three national group purchasing organizations (GPOs) in the U.S. for its OviTex and OviTex PRS products and intends to establish contracts with additional GPOs and integrated delivery networks (IDNs) to expand hospital account access. Revenue is primarily generated from sales of OviTex and OviTex PRS products in the U.S., with some sales occurring in Europe. The company serves the hernia repair surgery market in the U.S., which comprises approximately 1.2 million procedures annually, including complex and moderate ventral hernia repairs and abdominal wall reconstructions (105,000), simple ventral hernia repairs (395,000), inguinal hernia repairs (645,000), and hiatal hernia repairs (42,000). Its target markets include hernia repair, plastic and reconstructive surgery, and broader soft-tissue reconstruction.
Advancements in Soft-Tissue Reconstruction: TELA Bio s Strategic Innovations and Inducement Efforts MALVERN, Pa. Nov. 01, 2024 TELA Bio, Inc. (NASDAQ: TELA), a distinguished player in the medical technology sphere, continues to assert its innovative prowess in the domain of soft-tissue reconstruction solutions. Known for consistently pushing the envelope in medical technology, the company has recently enacted significant moves that underscore its commitment to developing advanced, patient-centric surgical products. Stimulating Growth through Strategic Inducements In a recent announcement highlighting their strategic human resource initiatives, TELA Bio revealed that its Compensation Committee has approved ...
TELA Bio, a leading innovator in the field of regenerative medicine, has recently announced the commercial launch of their groundbreaking product, Robotic-Compatible OviTex IHR. This cutting-edge solution aims to address the need for a more natural repair in inguinal hernia procedures, which account for over 665,000 surgeries conducted annually in the United States. Not only does this advanced technology revolutionize the way hernias are treated, but it also signifies the impressive growth and success of TELA Bio Inc as evident from their record-breaking revenue increase.TELA Bio s Robotic-Compatible OviTex IHR:Inguinal hernias, characterized by a protrusion of abdominal tissues or organs through the inguina...
Tela Bio Inc’s Comment on Sales, Marketing and Customers
The company markets its products primarily through a direct sales force based mainly in the United States, with additional sales representatives in the United Kingdom and European Union. It also utilizes independent contractors and distributors in the U.S. and certain European countries. The company holds contracts with three national group purchasing organizations (GPOs) in the U.S. for its OviTex and OviTex PRS products and intends to establish contracts with additional GPOs and integrated delivery networks (IDNs) to expand hospital account access. Revenue is primarily generated from sales of OviTex and OviTex PRS products in the U.S., with some sales occurring in Europe. The company serves the hernia repair surgery market in the U.S., which comprises approximately 1.2 million procedures annually, including complex and moderate ventral hernia repairs and abdominal wall reconstructions (105,000), simple ventral hernia repairs (395,000), inguinal hernia repairs (645,000), and hiatal hernia repairs (42,000). Its target markets include hernia repair, plastic and reconstructive surgery, and broader soft-tissue reconstruction.
Sources:
Tela Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tela Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on Tela Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
198.8 %